CL2022000894A1 - Moduladores atf6 y sus usos. - Google Patents

Moduladores atf6 y sus usos.

Info

Publication number
CL2022000894A1
CL2022000894A1 CL2022000894A CL2022000894A CL2022000894A1 CL 2022000894 A1 CL2022000894 A1 CL 2022000894A1 CL 2022000894 A CL2022000894 A CL 2022000894A CL 2022000894 A CL2022000894 A CL 2022000894A CL 2022000894 A1 CL2022000894 A1 CL 2022000894A1
Authority
CL
Chile
Prior art keywords
atf6
modulators
disease
pyrazole
treatment
Prior art date
Application number
CL2022000894A
Other languages
English (en)
Inventor
Sebastian Belmar
Brahmam Pujala
Sebastian Bernales
Pooja Thakral
Balaji Dashrath Sathe
Díaz Gonzalo Andrés Ureta
Original Assignee
Praxis Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biotech LLC filed Critical Praxis Biotech LLC
Publication of CL2022000894A1 publication Critical patent/CL2022000894A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Liquid Crystal Substances (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS DERIVADOS DE PIRAZOL, MODULADORES ATF6; COMPOSICIÓN FARMACÉUTICA; Y SU USO EN EL TRATAMIENTO DE UN ENFERMEDAD SELECCIONADA DE CÁNCER, ENFERMEDAD NEURODEGENERATIVA O ENFERMEDAD VASCULAR.
CL2022000894A 2019-10-09 2022-04-07 Moduladores atf6 y sus usos. CL2022000894A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962913126P 2019-10-09 2019-10-09

Publications (1)

Publication Number Publication Date
CL2022000894A1 true CL2022000894A1 (es) 2023-01-13

Family

ID=72852648

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000894A CL2022000894A1 (es) 2019-10-09 2022-04-07 Moduladores atf6 y sus usos.

Country Status (12)

Country Link
US (1) US20220389001A1 (es)
EP (1) EP4041727A1 (es)
JP (1) JP2022552231A (es)
KR (1) KR20220086597A (es)
CN (1) CN115135645A (es)
AU (1) AU2020361484A1 (es)
BR (1) BR112022006734A2 (es)
CA (1) CA3156839A1 (es)
CL (1) CL2022000894A1 (es)
IL (1) IL291963A (es)
MX (1) MX2022004212A (es)
WO (1) WO2021069701A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019247533B2 (en) * 2018-04-06 2023-09-28 Altos Labs, Inc. ATF6 inhibitors and uses thereof
JP2021522253A (ja) * 2018-04-25 2021-08-30 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用

Also Published As

Publication number Publication date
US20220389001A1 (en) 2022-12-08
BR112022006734A2 (pt) 2022-09-06
KR20220086597A (ko) 2022-06-23
CA3156839A1 (en) 2021-04-15
AU2020361484A1 (en) 2022-05-12
WO2021069701A1 (en) 2021-04-15
AU2020361484A9 (en) 2023-06-29
EP4041727A1 (en) 2022-08-17
CN115135645A (zh) 2022-09-30
IL291963A (en) 2022-06-01
JP2022552231A (ja) 2022-12-15
MX2022004212A (es) 2022-06-08

Similar Documents

Publication Publication Date Title
CL2023000973A1 (es) Inhibidores de ras
CL2023000974A1 (es) Inhibidores de ras
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2023000972A1 (es) Inhibidores de ras
CO2020010303A2 (es) Conjugados de il-15, y sus usos
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
ECSP19029982A (es) Moduladores de calpaínas y usos terapeuticos de los mismos
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CO2017004782A2 (es) Conjugados de anticuerpo- farmaco
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
BR112017021245A2 (pt) Anticorpo anti-c-met e conjugado anticorpo anti- c-met-fármaco citotóxico e uso farmacêutico do mesmo
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CL2020002573A1 (es) Inhibidores atf6 y sus usos.
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CO2021003530A2 (es) Conjugados de interleuquina 10 y usos de los mismos
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
BR112022001336A2 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.